Dr. Seen is the founder and CEO of GPCR Therapeutics, Inc. since 2013 and before then, he served as a managing director at Macrogen. Previously, Dr. Seen worked at Neurogenex(later Newgex) from 2001 to 2012 and led M&A with Boram Pharm. Co., Inc. as a CEO. Earlier in his career, he worked as a biotech researcher at LG Chemical.

Dr. Seen earned his BS, MS and Ph.D from Seoul National University.

Dr. Cardarelli is the vice president of R&D and is the CSO of GPCR Therapeutics, Inc. She served as a vice president of Cell Biology and Pharmacology at Bristol-Myers Squibb (BMS) where she was leading multiple targeted oncology programs and was a critical contributor to immuno-oncology projects. Previously, Dr. Cardarelli worked at Medarex (later acquired by BMS) as a vice president. Earlier in her career, she worked at Corixa, Coulter, and Tanabe.

Dr. Cardarelli earned her Ph.D from Albany Medical College.

Ms. Kim received her BS from Seoul National University and admitted to the Korean patent bar in 2001.

Dr. Fung has drug development experience targeting membrane proteins, including transporters and GPCRs. He worked at CRI Biotech and Sutro Biopharma. Previously, Dr. Fung co-founded ProNovus Bioscience, a protein reagent company.

Dr. Fung earned his PhD from the Stanford University School of Medicine.

Dr. Caculitan has drug development experience in immunology, oncology, and cancer immunotherapy. Before joining GPCR Therapeutics, she worked at Gritstone Oncology and Genentech.

Dr. Caculitan completed her Ph.D. at UC-Berkeley.